Oxurion stops investing in cancer spinout, reduces head count
Oxurion is stopping investing in its oncology spinout and narrowing its focus to its two clinical assets. The restructuring will affect “a number” of people who work at Oxurion and put the biotech all in on two potential treatments for retinal vascular diseases.